Prior Intimation for Board Meeting scheduled to be held on 14th February, 2026 to consider and approve unaudited financial results for the quarter ended 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech has informed the BSE that a meeting of its Board of Directors is scheduled for 14th February 2026. The main agenda is to consider and approve the unaudited financial results for the quarter ended 31st December 2025 (Q3 FY26). The company has also reminded that the trading window for insiders will remain closed until 16th February 2026 and reopen on 17th February 2026. This is a routine regulatory disclosure under SEBI LODR Regulation 29(1). No financial numbers or business updates are shared in this filing.
No direct impact on shareholders — this is a procedural notice. Investors should watch for the actual Q3 results when announced on or after 14th February 2026, as the numbers could move the stock.